Johnson & Johnson $JNJ is Edgar Lomax Co. VA's 3rd Largest Position

Key Points

• Edgar Lomax Co. VA increased its holdings in Johnson & Johnson by 17.7%, owning 446,295 shares valued at approximately $74 million, making it the company's third-largest shareholder.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, surpassing analyst expectations and achieving a 5.8% year-over-year revenue increase to $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, representing a 2.9% dividend yield and a payout ratio of 55.61%.

Edgar Lomax Co. VA grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 446,295 shares of the company's stock after purchasing an additional 66,955 shares during the quarter. Johnson & Johnson makes up about 4.6% of Edgar Lomax Co. VA's portfolio, making the stock its 3rd largest position. Edgar Lomax Co. VA's holdings in Johnson & Johnson were worth $74,014,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth approximately $47,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the first quarter worth approximately $49,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the first quarter valued at approximately $52,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $50,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE:JNJ traded up $0.7890 during midday trading on Wednesday, hitting $178.5890. 9,028,878 shares of the company's stock were exchanged, compared to its average volume of 9,045,183. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company has a market cap of $430.10 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 2.24 and a beta of 0.41. The stock has a 50 day moving average price of $162.13 and a 200-day moving average price of $158.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. UBS Group boosted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Finally, Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.